Pharmaceutical Executive-04-01-2020

For Sandra Horning, this year's Healthcare Businesswomen’s Association Woman of the Year, harnessing the patient experience has been the driving force in a career-spanning-and service-focused-mission to fight disease and accelerate the delivery of new medicines.

Recognizing that diversity and inclusion is no longer simply a “nice to have,” pharma has boosted efforts in this areas. But just how far are new industry initiatives moving the needle on D&I?

Speculating the downstream impact on industry practices is just that right now-speculation. What is sure is some things will never be the same, and some things could even get better.

The key to success in a hypercompetitive marketplace is to create targeting plans that get ahead of tomorrow’s prescriptions.

With coronavirus a stark backdrop, European initiative pushes for “fair” drug prices to spur investment in pharma innovation.

A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.

Emergency funds for research, public health, and economic disaster raise access issues.

Strategies for those chief information officers taking the digital reins at their organizations.

Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.

Although still tightly regulated, healthcare industry stakeholders-buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies-are cautiously optimistic that the Czech Republic will further close the gap with Western Europe.